These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7167850)

  • 1. [Myelopoietic effect of medroxyprogesterone acetate at high parenteral doses in the cancer patient].
    Gustavo Gercovich F; Morgenfeld E; Dragosky M; Murro H; Sorrentino M; Presman A; Martínez RE
    Sangre (Barc); 1982; 27(5):883-90. PubMed ID: 7167850
    [No Abstract]   [Full Text] [Related]  

  • 2. [The protective effect of medroxyprogesterone acetate in patients with ovarian cancer treated with chemotherapy].
    Enzelsberger H; Sevelda P; Salzer H
    Gynakol Rundsch; 1988; 28 Suppl 2():195-7. PubMed ID: 2976722
    [No Abstract]   [Full Text] [Related]  

  • 3. Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
    Wils JA
    Chemioterapia; 1988 Feb; 7(1):60-2. PubMed ID: 2967738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients.
    Lelli G; Angelelli B; Zanichelli L; Strocchi E; Mondini F; Monetti N; Piana E; Pannuti F
    Chemioterapia; 1984 Oct; 3(5):327-9. PubMed ID: 6241849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of medroxyprogesterone acetate (MAP) in high doses on chlorambucil-induced bone marrow depression. Preliminary results].
    Martoni A; Giovannini M; Pollutri E; Burroni P; Saccani-Jotti G; Pannuti F
    Arch Sci Med (Torino); 1982; 139(4):449-53. PubMed ID: 6220686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolizing and anti-pain effect of the short-term treatment with medroxyprogesterone acetate (MAP) at high oral doses in oncology.
    Pannuti F; Burroni P; Fruet F; Piana E; Strocchi E; Di Marco AR; Cricca A; Camaggi CM
    Panminerva Med; 1980; 22(3):149-56. PubMed ID: 6451859
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of medroxyprogesterone acetate on cerebral blood flow].
    Ikeda T; Kaneko M; Mori N
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Mar; 42(3):285-6. PubMed ID: 2139690
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficacy of autologous preserved marrow on patients undergoing myelodepressive therapeutic treatment].
    Polese E; Massenti S; Rossi-Torelli M
    Minerva Med; 1970 Sep; 61(77):4159-62. PubMed ID: 4921987
    [No Abstract]   [Full Text] [Related]  

  • 9. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
    Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
    Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group Study.
    Altman SJ; Stephens RL; Bonnet JD
    Cancer Treat Rep; 1982 Sep; 66(9):1781-2. PubMed ID: 6288240
    [No Abstract]   [Full Text] [Related]  

  • 12. Post-chemotherapy lymphopoiesis in patients with solid tumors is characterized by CD4+ cell proliferation.
    Sara E; Kotsakis A; Souklakos J; Kourousis C; Kakolyris S; Mavromanolakis E; Vlachonicolis J; Georgoulias V
    Anticancer Res; 1999; 19(1A):471-6. PubMed ID: 10226584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: Levamisole and bone-marrow restoration after chemotherapy.
    Lods JC; Dujardin P; Halpern GM
    Lancet; 1976 Mar; 1(7958):548. PubMed ID: 55833
    [No Abstract]   [Full Text] [Related]  

  • 14. [The state of hemopoiesis in the regional perfusion of malignant tumors of the extremities with sarcolysin, thio-TEPA and cyclophosphane].
    Levin AO; Babinina VF
    Vopr Onkol; 1967; 13(2):48-54. PubMed ID: 4971006
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in marrow myelopoietic and lymphoid cell counts after repeated cyclophosphamide administration in the rat.
    Berger J
    Haematologia (Budap); 1981 Dec; 14(4):407-16. PubMed ID: 7344975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
    Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
    J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progestational agents and bone metastasis in breast cancer].
    Leriche N; Bonneterre J
    Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone: a novel tool for treating bone marrow depletion in cancer patients caused by chemotherapeutic drugs and ionizing radiation.
    Whitfield JF
    Cancer Lett; 2006 Nov; 244(1):8-15. PubMed ID: 16540235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Do anabolic steroids protect bone marrow during cytostatic therapy?].
    Kopera H
    Med Klin; 1980 Jul; 75(15):539-43. PubMed ID: 7001201
    [No Abstract]   [Full Text] [Related]  

  • 20. Myelosuppressive effects of antineoplastic drugs.
    Exp Hematol; 1985; 13 Suppl 16():1-121. PubMed ID: 3987833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.